Karlijn P M Suijkerbuijk

44PUBLICATIONS
121CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersAutoimmunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Jun 26, 2026
Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

|May 04, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

|Jan 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen

|Jan 23, 2026
Author Correction: Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.

Mick J M van Eijs, M Marlot van der Wal, Hedi-Britt Klotškova

|Nov 18, 2025
Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.

Mick J M van Eijs, M Marlot van der Wal, Hedi-Britt Klotškova

|Sep 02, 2025
Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment.

S Van Dam, D Krijgsman, E Küçükköse

Pageof 8

Frequent Collaborators

17 joint publications

Ellen W Kapiteijn

14 joint publications

Michel W Wouters

11 joint publications

Rik J Verheijden

9 joint publications

Astrid Van der Veldt